The YELLOWSTONE Program is a series of Phase 3 clinical studies for people with moderately to severely active Crohn’s disease. These studies will evaluate the safety and effectiveness of an oral investigational study drug (ozanimod) which is taken once daily. Ozanimod is not a biologic, injection or infusion. Ozanimod is an immune regulator designed to change the body’s immune system response (when the body defends itself), potentially reducing inflammation and overall disease activity. The goal is to potentially help people living with this disease reduce symptoms (remission/response).
Is there a better way to optimise disease control for patients with ulcerative colitis? A new study aims to find out
Achieving and maintaining effective control of ulcerative colitis is the goal of treatment, but, as all patients know, it can be a challenge. Current management of mild-to-moderate ulcerative colitis is typically guided by symptoms, with therapy increased during a flare and decreased when controlled.
EFCCA has been collaborating with Medscape on a training session about biosimilars and the patients' perspective which is addressed to Healthcare providers. The training session includes a video simulation and a leaflet addressed to patients and to be distributed by physicians during their medical examination.
For more information about this project please contact the EFCCA office.
EFCCA is involved in an exciting EU Research Project under the Innovative Medicines Initiative (IMI 2) (Horizon 2020).
The ImmUinverse project main goal is the improved diagnostic and therapeutic options for patients living with ulcerative colitis and atopic dermatitis. New insights into disease severity and progression will enable personalised therapy for each individual patient.
The global impact of COVID-19 has been overwhelming and without pause, accelerating at lightning speed, changing our lives and our way of seeing the world. In recent months, unfortunately, the philosophy of our organization, which is to create spaces for meeting, for dialogue between the various associations and all the interlocutors. has also had to change.
Final Results available!
We are excited to share our findings of the survey “The impact of perianal fistula in Crohn’s disease on quality of life” which is being presented virtually at the 16th ECCO Congress (2nd – 3rd and 8th – 10th July, 2021.) Check otu the results and read more: https://www.efcca.org/en/final-results-perianal-fistula-survey-available
About the Survey
Make IBD work!
19 May World IBD Day – Awareness raising campaign
New survey on the indirect costs of IBD. The aim of the study is to assess the influence of IBD on the patients productivity at work and relevant costs for society.
IBD and parenthood - Survey on couples with IBD and their offspring
FCCA Academy - Training Certified Patient Experts
EFCCA is embarking on an exciting new project under the title "EFCCA Academy- Training Certified Patient Experts". The pilot phase was launched in mid 2018.